Mark Gelfand, Howard Levin Discuss Coridea, Ardian and How They’re Innovating Medtech Innovation

Over the past decade, no other Medtech start-up has moved markets as much or as quickly as Ardian, the godfather of the renal denervation surge a decade ago. But the gold rush dried up in 2014 when Medtronic delivered disappointing clinical trial news that left many to declare “Renal Denervation is Dead.” Well, if we may borrow from Monty Python, renal denervation is not dead yet.  In this two-part podcast, we talk with Mark Gelfand and Howard Levin, the principals of Coridea, who developed Ardian’s approach. We'll talk with them about their path to creating Coridea, the state of innovation, and, of course, how the Ardian “Opera” influenced them going forward.